CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Swiss National Bank

Swiss National Bank lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 0.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 157,600 shares of the company’s stock after selling 1,100 shares during the quarter. Swiss National Bank owned about 0.19% of CRISPR Therapeutics worth $7,404,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Cetera Investment Advisers increased its stake in shares of CRISPR Therapeutics by 451.3% in the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock valued at $2,324,000 after purchasing an additional 27,915 shares during the period. CWM LLC boosted its holdings in shares of CRISPR Therapeutics by 11,871.1% in the second quarter. CWM LLC now owns 22,386 shares of the company’s stock valued at $1,209,000 after acquiring an additional 22,199 shares in the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after acquiring an additional 22,583 shares in the last quarter. Granite Bay Wealth Management LLC bought a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $2,375,000. Finally, International Assets Investment Management LLC bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $1,825,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Activity

In other news, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,382 shares of company stock worth $1,917,679. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Stock Up 5.3 %

CRSP stock opened at $50.40 on Tuesday. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10. The company has a market cap of $4.30 billion, a price-to-earnings ratio of -17.95 and a beta of 1.67. The company has a 50 day moving average of $47.98 and a two-hundred day moving average of $51.73.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the prior year, the firm earned ($1.41) EPS. On average, research analysts anticipate that CRISPR Therapeutics AG will post -5.2 EPS for the current year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Truist Financial reduced their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Stifel Nicolaus reduced their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus target price of $74.94.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.